AlloVir (ALVR) Competitors $2.50 -0.05 (-1.96%) As of 07/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. OSTX, CRVO, AVTX, IPA, RENB, KLRS, BLUE, ADVM, VRCA, and DTILShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include OS Therapies (OSTX), CervoMed (CRVO), Avalo Therapeutics (AVTX), ImmunoPrecise Antibodies (IPA), Renovaro (RENB), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors OS Therapies CervoMed Avalo Therapeutics ImmunoPrecise Antibodies Renovaro Kalaris Therapeutics bluebird bio Adverum Biotechnologies Verrica Pharmaceuticals Precision BioSciences OS Therapies (NYSE:OSTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment. Which has stronger valuation & earnings, OSTX or ALVR? OS Therapies is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-1.98AlloVirN/AN/A-$190.42M-$20.23-0.12 Is OSTX or ALVR more profitable? OS Therapies' return on equity of 0.00% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% AlloVir N/A -71.03%-61.27% Do insiders and institutionals hold more shares of OSTX or ALVR? 66.1% of AlloVir shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer OSTX or ALVR? OS Therapies currently has a consensus target price of $18.00, suggesting a potential upside of 958.82%. Given OS Therapies' stronger consensus rating and higher probable upside, research analysts clearly believe OS Therapies is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to OSTX or ALVR? In the previous week, OS Therapies had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for OS Therapies and 0 mentions for AlloVir. OS Therapies' average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score. Company Overall Sentiment OS Therapies Neutral AlloVir Neutral SummaryOS Therapies beats AlloVir on 8 of the 12 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.61M$209.58M$5.61B$9.11BDividend YieldN/AN/A5.24%4.01%P/E Ratio-0.12N/A27.9620.25Price / SalesN/A253.11430.8999.65Price / CashN/A22.4437.4658.16Price / Book0.096.158.045.49Net Income-$190.42M-$96.61M$3.18B$250.27M7 Day PerformanceN/A12.45%3.68%4.80%1 Month Performance-13.79%10.71%4.10%7.68%1 Year Performance-86.41%6.49%29.59%16.36% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$2.50-2.0%N/A-86.0%$12.61MN/A-0.12110Gap UpOSTXOS Therapies1.7059 of 5 stars$1.88+2.2%$18.00+857.4%N/A$52.82MN/A-2.19N/ANews CoverageGap UpCRVOCervoMed3.3353 of 5 stars$6.28+3.8%$27.63+339.9%-55.1%$52.65M$9.74M-2.884Positive NewsAVTXAvalo Therapeutics3.0036 of 5 stars$4.99+4.4%$30.00+501.2%-60.2%$51.76M$440K0.0040IPAImmunoPrecise Antibodies3.0921 of 5 stars$1.06-4.5%$4.00+277.4%+54.4%$50.80M$18.16M-0.9180Positive NewsUpcoming EarningsGap DownRENBRenovaro1.9236 of 5 stars$0.29-1.3%N/A-81.4%$50.38MN/A-0.3820News CoverageKLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49MN/A0.00110Positive NewsGap UpBLUEbluebird bio1.5935 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520ADVMAdverum Biotechnologies4.5787 of 5 stars$2.15-7.3%$23.80+1,007.0%-67.4%$48.47M$1M-0.34190Positive NewsVRCAVerrica Pharmaceuticals4.505 of 5 stars$0.53+1.4%$8.00+1,409.1%-90.5%$48.34M$7.57M-0.4440News CoverageGap DownDTILPrecision BioSciences4.2697 of 5 stars$4.20-2.3%$47.00+1,019.0%-54.6%$47.68M$68.70M-2.09200Gap Down Related Companies and Tools Related Companies OSTX Alternatives CRVO Alternatives AVTX Alternatives IPA Alternatives RENB Alternatives KLRS Alternatives BLUE Alternatives ADVM Alternatives VRCA Alternatives DTIL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
